Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Addex Therapeutics Ltd News

    0,1155 CHF +0,43% +0,0005 CHF
    In : 0,1181 € | 26.04.24 17:31:30 SIX Swiss Exchange aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0MSH6
    ISIN: CH0029850754
    US-Symbol: ADDXF
    Typ: Aktie

    Addex Therapeutics Ltd News

    19.04.24 - GlobeNewswire
    Addex to Present at the Swiss Biotech Day 2024
    Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug ...
    18.04.24 - GlobeNewswire
    Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
    Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate ...
    11.04.24 - GlobeNewswire
    Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
    Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug ...
    03.04.24 - GlobeNewswire
    Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
    Addex receives CHF5M and 20% share of Neurosterix
    14.03.24 - GlobeNewswire
    Addex to Present at the Bio-Europe Spring 2024 Conference
    Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug discovery and ...
    31.01.24 - GlobeNewswire
    Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
    Ad Hoc Announcement Pursuant to Art. 53 LR
    09.01.24 - GlobeNewswire
    Addex to Present at the Swiss Equities Baader Conference
    Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug ...
    05.01.24 - GlobeNewswire
    Addex to Present at Biotech Showcase™ 2024
    CEO to provide update on allosteric modulator pipeline clinical and preclinical development
    20.12.23 - GlobeNewswire
    Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
    Ad Hoc Announcement Pursuant to Art. 53 LR
    14.12.23 - GlobeNewswire
    Addex Creates Treasury Shares
    Ad Hoc Announcement Pursuant to Art. 53 LR
    29.11.23 - GlobeNewswire
    Addex Reports Q3 2023 Financial Results and Provides Corporate Update
    ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 mGlu2 NAM cognition program receives a €4 million Eurostars ...
    28.11.23 - GlobeNewswire
    Addex Convenes Extraordinary General Meeting
    Ad Hoc Announcement Pursuant to Art. 53 LR
    23.11.23 - GlobeNewswire
    Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
    Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug ...
    14.11.23 - GlobeNewswire
    Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
    Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR
    08.11.23 - GlobeNewswire
    Addex Regains Nasdaq Listing Compliance
    Ad Hoc Announcement Pursuant to Art. 53 LR
    02.11.23 - GlobeNewswire
    Addex Announces Participation in the Bio-Europe 2023 Conference
    Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug ...
    20.10.23 - GlobeNewswire
    Addex Completes ADS Ratio Change
    Ad Hoc Announcement Pursuant to Art. 53 LR
    06.10.23 - GlobeNewswire
    Addex Announces Plan to Implement ADS Ratio Change
    Ad Hoc Announcement Pursuant to Art. 53 LR
    20.09.23 - GlobeNewswire
    Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
    Addex led consortium wins Eurostar s grant to deliver clinical candidates to treat mild neurocognitive disorder s Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, ...
    06.09.23 - GlobeNewswire
    Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
    Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage pharmaceutical company pioneering allosteric modulation-​based drug ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »